Arrowhead Pharmaceuticals, Inc.
http://arrowheadpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Arrowhead Pharmaceuticals, Inc.
ESC: Arrowhead Aims For Best-In-Class In FCS
But Ionis might be first to reach this small but potentially lucrative market.
Finance Watch: Actuate Launches 15th Biopharma IPO In The US For 2024
Public Company Edition: Actuate Therapeutics grossed $22.4m in its first-time offering, while already-public companies recently tapped a variety of sources for funding. Arrowhead negotiated a credit facility for up to $500m and ANI sold $275m worth of notes, among other financings.
What To Look Out For At ESC 2024
Full data on heart disease products from Alnylam, Bayer and others will take center stage at the cardiology meeting later this month.
Arrowhead’s Focus On Plozasiran Intensifies Competition With Ionis
Arrowhead’s in-house, late-stage cardiovascular disease programs will center on triglyceride-lowering plozasiran while it seeks a partner to fund Phase III for cholesterol-reducing zodasiran.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
-
- Ablaris Therapeutics, Inc.
- Alvos Therapeutics, Inc. (formerly Mercator Therapeutics, Inc.)
- Arrowhead Research Corporation
- Calando Pharmaceuticals, Inc.
- Unidym
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice